Peps
What is SLU-PP-332?
SLU-PP-332 is a lab-made small molecule, not a peptide, that switches on the estrogen-related receptors involved in how muscle burns fuel. It is called an "exercise mimetic" because in mice it triggered some of the same metabolic changes as aerobic exercise. All published evidence comes from animal and cell studies.
Biological role or research focus
"Exercise mimetic" metabolism research in mice.
These are mouse results from the group that developed the compound. Mouse metabolism differs from human metabolism, and none of this shows that SLU-PP-332 is effective or safe for weight loss or fitness in people.
Role reference: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Names you may encounter
SLU PP 332 · SLU-PP332 · ERR agonist SLU-PP-332
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Small-molecule agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ); not a peptide
- Research focus
- "Exercise mimetic" metabolism research in mice
- Featured evidence
- Animal study
- Source check
- October 4, 2026
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Biology & proposed mechanism
The estrogen-related receptors (ERRs) are nuclear receptors that turn on genes for mitochondria and fat burning, the same programs that endurance exercise activates. SLU-PP-332 activates all three ERRs. In mice this raised energy use and fat burning; whether the same happens safely in people has not been tested.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Research context & identity
This profile covers early metabolic research. SLU-PP-332 has no approved medical use and no published human trials were found when this page was checked. Recent analytical papers describe how anti-doping laboratories can detect it, because of its potential misuse in sport. Sellers offer it as a research chemical.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| SLU-PP-332 in mouse models of obesity and metabolic syndrome (2024) | Animal study | Diet-induced obese mice and genetically obese (ob/ob) mice. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal study · 2024
SLU-PP-332 in mouse models of obesity and metabolic syndrome
What did this publication test, and what did it find?
- Population / model
- Diet-induced obese mice and genetically obese (ob/ob) mice.
- Study design
- Mice were given SLU-PP-332 and compared with untreated mice on energy expenditure, fat burning, fat mass, body weight and insulin sensitivity.
- Main finding
- Treated mice burned more energy and more fat, gained less fat mass, lost weight and showed better insulin sensitivity than untreated mice.
- Limits & context
- These are mouse results from the group that developed the compound. Mouse metabolism differs from human metabolism, and none of this shows that SLU-PP-332 is effective or safe for weight loss or fitness in people.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming SLU-PP-332 as an intervention was found on ClinicalTrials.gov when we last checked (October 8, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
There is no human safety data. Long-term effects of switching on these receptors throughout the body, including on the heart, liver and hormones, are unknown. Products sold online are unregulated and their purity cannot be assumed.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Evidence boundaries
These are mouse results from the group that developed the compound. Mouse metabolism differs from human metabolism, and none of this shows that SLU-PP-332 is effective or safe for weight loss or fitness in people.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on the lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. Not named under S4.4 metabolic modulators (which lists AMPK activators, PPAR-delta and Rev-erb agonists). source
Checked October 8, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
Some seller links are affiliate links, and codes such as PEPSRADAR credit PepsRadar; PepsRadar may earn a commission. Affiliate disclosure. For laboratory research use only. Not for human consumption.
SLU-PP-332 (5 mg)
Offline Peptides · Vendor-labeled research use only
$42.00
Listed in stock · Price checked 2026-10-09
Options may vary. Shipping and tax excluded.
10% off with code PEPSRADAR10 · PepsRadar earns a commission on this code
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides, Peptide.Express, Offline Peptides, Alera Research, Pinnacle Peptide Labs. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is SLU-PP-332 a peptide, and has it been tested in people?
- What material, population, and route were actually studied?
- These are mouse results from the group that developed the compound. Mouse metabolism differs from human metabolism, and none of this shows that SLU-PP-332 is effective or safe for weight loss or fitness in people.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is SLU-PP-332 a peptide, and has it been tested in people?
It is a small molecule, not a peptide, and no published human trials were found. The evidence is from mice and cells, so claims that it replaces exercise or causes weight loss in people are unproven.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: A Synthetic ERR Agonist Alleviates Metabolic Syndrome · 2024 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.